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use this model to investigate the role of conduction and repolarization abnormalities in the
arrhythmogenic mechanism.
Methods and Results: The ECGs were obtained from anesthetized wild-type and Scn5a+/− mice,
before and after administration of the known pro- and antiarrhythmic agents flecainide and quinidine.
The ECG intervals were measured and their dispersions calculated. Scn5a+/− hearts showed
ventricular arrhythmias, ST elevation, and conduction disorders including increased QT dispersion,
accentuated by flecainide. Quinidine did not cause ventricular arrhythmias but exerted variable
effects on ST segments and worsened conduction abnormalities.
Conclusions: The ECG features in an Scn5a+/− mouse establish it as a suitable model for Brugada
syndrome and demonstrate abnormal conduction and repolarization phenomena. Altered QT
dispersion, taken to indicate increased transmural repolarization gradients, may be useful in clinical
risk stratification.
© 2010 Elsevier Inc.Open access under CC BY license. Introduction
The Brugada syndrome (BrS) is associated with increased
incidences of polymorphic ventricular tachycardia (VT),
exacerbated by flecainide but reduced by quinidine. Two
major hypotheses have been suggested for this arrhythmo-
genicity. On the one hand, a depolarization defect might slow
right ventricular (RV) action potential (AP) conduction,1
leading to a predisposition to reentrant arrhythmias. Alterna-
tively, alterations in the time course of AP repolarization
might result in a shortening of epicardial relative to
endocardial AP durations (APDs), thereby increasing
repolarization heterogeneities.2
These cellular mechanisms are potentially reflected in the
electrocardiographic (ECG) features of BrS, of a persistent or
transient ST elevation in the right precordial V1-V3 leads,
often in combination with a pattern suggestive of right
bundle branch block. This ECG pattern is central to theauthor. Physiological Laboratory, University of
Site, Cambridge CB2 3EG, United Kingdom.
airemartin@gmail.com
sevier Inc.
ard.2010.05.015
Open access under CC BY license. diagnosis of BrS. Flecainide and other class 1C drugs are
often used to unmask the ST elevation,3 whereas there are
early indications that quinidine can normalize the ST
elevation seen in BrS.4
A significant proportion of BrS cases are associated
with an inherited loss of Na+ channel function. This has
prompted its recent experimental modeling using a
genetic Scn5a+/− murine mutant, which shows a 50%
reduction in sodium current in cellular studies and higher
incidences of arrhythmogenesis compared to wild type
(WT) when studied in Langendorff preparations.5 Recent
studies have demonstrated both a conduction delay and
increased repolarization gradients across the RVwall in the
Scn5a+/−model.6 However, thus far, there have been few in
vivo ECG studies in murine models whether for Scn5a+/− or
in other primary electrophysiological disease. Yet, the ECG
provides important measures of electrophysiological func-
tion, complementing studies of membrane currents at the
cellular level and of AP waveforms in whole heart
preparations. It has been the gold standard for determining
effects of pharmaceutical compounds on cardiac electro-
physiology. Furthermore, ECG recordings permit electro-
Fig. 1. Typical ECG complex from a WT heart before pharmacological
manipulation. The murine ECG differs from the human ECG in that the
major deflection (a) representing the QRS is followed by a secondary slower
deflection (b), and sometimes, a subtle third positive or negative wave
(c) follows. We did not consistently find a (c) wave on our ECGs and
therefore used the (b) wave to measure the QT interval.
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inputs to the heart.
Most available ECG studies have used the dog as a
predictive preclinical species representing human electro-
physiology, but BrS models are limited to pharmacological
perfused wedge preparations. The recent extensive introduc-
tion of whole animal genetic murine models in studies of
arrhythmic disease now requires the extension of ECG
techniques to the mouse. Despite differences between
murine and human ECG characteristics, particularly in
QRS and T-wave morphology, ECG analysis is currently
the only noninvasive method of studying cardiac electro-
physiology in the intact mouse. Parameters such as the PR
and QRS durations can give indications of conduction
velocities within the heart, which may also provide
indications of tendency toward reentrant arrhythmias. In
addition, measurements such as the QT interval, representing
the sum of ventricular depolarization and repolarization,7
may be used as a noninvasive surrogate for the APD and
thereby help clarify the arrhythmogenic mechanism and aid
clinical risk stratification.
The present experiments explore the extent to which ECG
features in the genetic Scn5a+/− murine model reproduce
the corresponding clinical phenotype, in particular in its
arrhythmic features and characteristic ST elevation. We then
use the murine model to explore for alterations in conduction
velocity and repolarization times that might thereby be
attributed to the Scn5a+/− mutation and compare these with
features that occur in human BrS. A characterization of these
may be useful in future studies assessing the effects of
possible pharmacological interventions for BrS, for which
the current mainstay of treatment is implanted cardioverter/
defibrillator implantation.Materials and methods
Mice aged 3 to 6 months were obtained from breeding
pairs of heterozygote Scn5a+/− and WT inbred 129/sv mice,
initially supplied by Harlan (UK). All procedures conformed
to the UK Animals (Scientific Procedures) Act 1986. Mice
were anesthetized intraperitoneally (IP) using Tribromoetha-
nol (Avertin) (Sigma-Aldrich, Poole, UK) and custom-made
chest and limb ECG leads attached. The anesthetic was
chosen as it affects hemodynamics and electrophysiology to a
lesser extent than other agents such as ketamine.8 A baseline
ECG recording was obtained, and then either flecainide (20
mg/kg; Sigma-Aldrich) or quinidine (100 mg/kg; Sigma-
Aldrich) was injected IP, and an ECG recording made for a
30-minute period. This flecainide dose has been used
previously9 on both WT mice and mice with an SCN5A-
1795insD mutation, in which it resulted in conduction
abnormalities, whereas the quinidine dose compares with
previous studies using 300 mg/kg IP in electrophysiological
studies10 or 100 to 150 mg/kg in noncardiological studies.
The ECG signals were amplified and bandpass filtered
between 15 and 1000 Hz using Neurolog amplifiers
(Preamplifier: Model NL-100; AC amplifier: Model
NL104) and filters (Model NL125/126, Digitimer, Welwyn
Garden City, Herts, UK), and then digitized using a 1401plusinterface (Cambridge Electronic Design, Cambridge, UK).
Analysis of ECG waveforms was performed using Spike2
software (Cambridge Electronic Design).
RR, PR, QRS, and QT intervals were measured from
the ECG traces. The murine ECG differs from the human
ECG in that the major deflection (a) representing the QRS
is often followed by a secondary slower deflection (b) and
sometimes a subtle third positive or negative wave (c),
shown in Fig. 1. Some investigators designate b as the T
wave and others c.11 We did not consistently find a c
wave on our ECGs and therefore used the b wave to
measure the QT interval, as shown. A heart rate correction
factor was used, derived from Mitchell et al8 of QTc =
QT/(RR/150)1/2, as the average RR interval in our mice
was 150 milliseconds. Ten measurements of each ECG
interval in both chest and limb leads were made for each
mouse. Differences in time intervals between hearts were
analyzed using Student t tests with a modified Bonferroni
correction factor.12Results
Ten WT and 10 Scn5a+/− hearts were studied. In each
group, 5 were subsequently exposed to flecainide and 5
to quinidine.Incidence of ventricular arrhythmia
None of the WT hearts studied showed incidences of
VT, whether before or after introduction of either flecainide
or quinidine. None of the Scn5a+/− hearts showed
incidences of VT before pharmacological intervention,
although 1 Scn5a+/− heart demonstrated a bigeminal ECG
pattern. However, the addition of flecainide then provoked
VT in 2 Scn5a+/− hearts and nonsustained VT in a further
heart (Fig. 2). Addition of quinidine did not lead to any
ventricular arrhythmias.
Fig. 2. Trace from a typical Scn5a+/− heart showing the onset of wide
complex tachycardia following the addition of flecainide.
435C.A. Martin et al. / Journal of Electrocardiology 43 (2010) 433–439Presence of ST elevation
In WT hearts, there was no evidence of ECG ST
elevation before pharmacological treatment. However, the
addition of flecainide did cause some minor ST-segment
elevation up to 0.09 ± 0.03 mV in the chest lead but not in
the limb lead. Addition of quinidine did not affect the ST
segment. Scn5a+/− hearts showed a degree of ST elevation
in the chest lead, with a mean of 0.17 ± 0.03 mV. With the
addition of flecainide, this significantly increased to a mean
ST elevation of 0.40 ± 0.07 mV (Fig. 3). The ST elevation
seen in untreated Scn5a+/− hearts was reduced to baseline
by the addition of quinidine in 2 hearts but actually was
slightly increased in 1 heart, from 0.16 to 0.22 mV.
We thus demonstrate the occurrence of ventricular
arrhythmias and chest lead ST elevation, particularly after
exposure to a flecainide challenge, for the first time in intact
anesthetized genetically modified animals used to model
BrS. This reproduces the diagnostic clinical ECG features of
the human condition and suggests that the murine Scn5a+/−
mutant would be an appropriate model to explore for and
identify those electrophysiological features that could be
attributable to a genetic loss of Na+ channel function.
Presence of atrioventricular block
Untreated WT hearts showed no atrioventricular (AV)
block. However, subsequent addition of flecainide and
quinidine each caused 1 of 5 hearts to develop 2:1 heart
block. Of 5 Scn5a+/− hearts, 2 showed short episodes of 2:1
AV block before exposure to flecainide. All 5 Scn5a+/−
hearts exposed to flecainide showed various degrees of heart
block, ranging from missed beats to persistent second-degree
block, with 2:1 to 6:1 block, complete heart block, and sinus
arrest (Fig. 4A, B). Interestingly, quinidine also produced
heart block, with 1 heart showing 2:1 and 3:1 block, and
another 3 showing block up to 5:1 (Fig. 4C, D).
ECG intervals
Untreated Scn5a+/− hearts showed increased RR and PR
intervals but statistically indistinguishable QRS and QT
intervals compared to WT. Both WT and Scn5a+/− miceshowed widespread alterations in ECG intervals following
the addition of either flecainide or quinidine. Both agents
increased ECG RR, PR, QR, and QT intervals (Fig. 5),
whether measured in the chest leads or the limb leads.
However, flecainide exerted larger effects on these ECG
intervals in Scn5a+/− than in WT. Consequently, when
Scn5a+/− and WT were compared a second time in the
presence of flecainide, the differences between the two
reached significance for all intervals recorded. In contrast,
quinidine increased the ECG intervals but did so to a similar
degree in both the WT and Scn5a+/− hearts, and so the only
difference between the two was then in the PR interval. All
these effects on cardiac conduction were observed in both the
chest lead and the limb lead of the ECG.
ECG dispersion
Scn5a+/− traces demonstrated increased dispersions in
ECG intervals, attributable to Na+ channel loss. Dispersions
of ECG intervals within each heart were explored by taking
measurements from 2 ECG leads simultaneously—both from
a chest lead and a limb lead (analogous to lead II), and the
difference between the two in each heart calculated (Fig. 6).
There was an increased difference between limb lead and
chest lead in QRS and QTc intervals for Scn5a+/− hearts
compared to WT hearts. Comparisons of the ECG dispersion
in a given heart indicated that in WT hearts both flecainide
and quinidine increased the dispersion to a significant level
for the QTc intervals. In the Scn5a+/− hearts, flecainide
increased the dispersion in both the QRS and QTc intervals.
In contrast, quinidine did not increase the dispersion in either.
Comparing WT and Scn5a+/− hearts after the addition of
flecainide revealed a further difference in the QRS and QTc
dispersions. However, the addition of quinidine served to
reduce the difference between WT and Scn5a+/− hearts to
statistically indistinguishable levels.Discussion
BrS is characterized by increased incidences of ventricular
arrhythmias exacerbated by flecainide but reduced by
quinidine, and with an association of a significant proportion
of cases with loss of function mutations involving the Na+
channel. The present experiments assessed the extent to which
intact anesthetized heterozygotic Scn5a+/− mice replicate the
ECG features of corresponding in vivo findings to allow them
to be used as an experimental model for this condition. We
then use this in vivo system to clarify ECG evidence for
abnormalities of conduction and repolarization that are
specifically attributable to loss of Na+ channel function.
The Scn5a+/− mouse replicates the ECG features
of BrS
These ECG studies demonstrated wide complex tachycar-
dias in the Scn5a+/− mice, which confirmed previous studies
describing VTs in Langendorff perfusion experiments.6 They
then went on to demonstrate their accentuation by flecainide.
This directly parallels its known arrhythmic effects in human
VT. In contrast, quinidine exerted an antiarrhythmic effect in
Fig. 3. A-D, Traces from chest leads (A, C) and limb leads (B, D) of a Scn5a+/− heart showing minor ST elevation before flecainide (A) and accentuated ST elevation
after flecainide (C) in the chest leads but no appreciable ST elevation in the limb leads either before (B) or after (D) addition of flecainide. E and F, ST elevation measured
from chest and limb leads for WT (E) and Scn5a+/− (F) hearts before and after the addition of flecainide or quinidine. TenWT and ten Scn5a+/− hearts were used, with
5 of each exposed to each drug. Results from chest leads are denoted by solid symbols; results from limb leads are denoted by open symbols. †Results of t tests comparing
WT and Scn5a+/− hearts giving values indicating significance. ⁎Results of t tests comparing values before and after drug in the same hearts giving values indicating
significance. #Results of t tests comparing values between chest and limb leads in the same hearts giving values indicating significance.
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of polymorphic VT in experimental canine pharmacological
perfused wedge preparations2 and its therapeutic antiarrhyth-
mic effects in human BrS.4
We then demonstrated for the first time that Scn5a+/−
mice show an ST elevation specific to the chest lead, which is
accentuated by flecainide. This directly correlates with the
clinically observed ST elevation and its provocation by
flecainide. Both these features are central to the ECG
diagnosis of human BrS. The murine Scn5a+/− system thus
provides an alternative to canine perfused wedge preparations
in which ST elevation could only be replicated using multiple
drug combinations rather than flecainide alone.13 Further-
more, the minor ST elevation in WT hearts with flecainide
also replicates clinical reports of Brugada-type ECGs in
normal patients treated with flecainide.14 Finally, the effect of
quinidine on ST elevation is mirrored in studies either
showing that quinidine can reverse the ST elevation4 or have a
variable effect upon the ST interval15 in BrS.The differences in morphology between the human and
murine ECGs mean that the ST segment is not identical
between the 2 species, and therefore, interpretations about ST-
segment elevation must be made with care. It is possible that
the ST elevation is a normal variant in the mice; however, the
lack of ST elevation in any of the WT mice before drug
administration would argue against this. The traces in the BrS
mice with flecainide do appear to reproduce the coved
appearance of a human BrS type 1 ECG. Furthermore, they
resemble the ST elevation seen in murine ECGs after ischemia
produced by occlusion of the left anterior descending artery.16The Scn5a+/− mouse shows ECG evidence for conduction
abnormalities directly attributable to loss of Na+ channel
function
BrS has been associated not only with abnormalities in
SCN5A but also mutations in several other genes. Our
experiments explored for ECG properties in Scn5a+/− mice
Fig. 4. Traces from Scn5a+/− hearts after flecainide challenge showing missed beats on a background of ST elevation (A) and high level AV block (B), and after
introduction of quinidine showing missed beats (C) and high-level AV block (D).
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identified with loss of Na+ channel function. These revealed
abnormalities in conduction and repolarization.
The intact anesthetized Scn5a+/− mice showed features
of second-degree AV block and increased PR intervals,
consistent with the longer conduction latencies previously
observed in Langendorff perfused Scn5a+/− hearts.6 These
findings are directly translatable to clinical observations.Fig. 5. ECG parameters from chest and limb leads measured as RR, PR, QRS, and
flecainide or quinidine. TenWT and ten Scn5a+/− hearts were used, with 5 of each
results from limb leads are denoted by open symbols. †T tests comparing WT and
values before and after drug in the same hearts giving values indicating significanGenetically heterogeneous groups of patients with BrS show
varying findings of either similar17 or longer18 PR intervals
and AV block; however, BrS patients with an identifiable
SCN5A mutation have been reported generally to show
longer PR intervals and more bradyarrhythmias19 than those
without an identifiable SCN5A mutation. Furthermore, loss-
of-function SCN5A mutations are associated with a hetero-
geneous range of conditions including Progressive CardiacQTc intervals for WT and Scn5a+/− hearts before and after the addition o
exposed to each drug. Results from chest leads are denoted by solid symbols
Scn5a+/− hearts giving values indicating significance. *T tests comparing
ce.f
;
Fig. 6. QRS (A) and QTc (B) dispersion measured as the difference in time
course in QRS or QTc intervals between chest leads and limb leads. Data are
shown for WT and Scn5a+/− hearts before and after the addition of
flecainide or quinidine. Ten WT and ten Scn5a+/− hearts were used, with 5
of each exposed to each drug. †T tests comparing WT and Scn5a+/− hearts
giving values indicating significance. *T tests comparing values before and
after drug in the same hearts with values indicating significance.
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with BrS. Together, these findings suggest that ECG features
of conduction delay seen in BrS may be attributable
specifically to the Na+ channel loss of function.
The conduction abnormalities in Scn5a+/− mouse are
exacerbated by flecainide
Flecainide exacerbated the conduction delay in all
mice, but particularly in the Scn5a+/−. This is consistent
with its actions in pharmacological Na+ channel block
when this is superimposed upon a preexisting reduction in
Na+ channel function caused by Scn5a+/−. These findings
directly correlate with clinical studies reporting that
flecainide increases PR intervals and QRS durations both
in control and BrS patients,17,20 with greater effects in the
latter.
That quinidine also increased conduction abnormalities
might suggest that theoretically it could worsen conduction
in cases of BrS with an already diseased conduction
system. However, in clinical trials, this has not been
seen,21 and the effects shown here may be due to the
relatively high doses of quinidine, in comparison to the
low doses used clinically, where the effects of blocking K+
channels are likely to be much stronger that those blocking
Na+ channels.
QT interval is not a direct correlate of APD
The clinical QT interval has been taken to be the sum
of depolarization and repolarization time courses. The
corresponding clinical findings vary, either reporting QTc
intervals in patients with BrS within a reference range22 or
that were significantly longer than controls.20 Several
studies17,20 have shown that the QTc interval is prolonged
with the introduction of flecainide both in BrS and control
groups, but more so in patients with BrS.
The reduced Na+ current in BrS has been suggested to
exaggerate the normally existing electrical heterogeneitywithin the ventricular wall and in particular accentuate
the AP notch in the RV epicardium. Pitzalis et al20 have
suggested that the greater the baseline AP notch, the
longer the induced AP prolongation, which should be
reflected in prolongation of the QT interval. However,
other studies have related electrophysiological abnormal-
ities in BrS with shortening of APDs in the RV
epicardium.2,6 This contrasts with the normal or slightly
prolonged QTc interval seen both clinically and in the
present experiments.
It is possible that the QTc does not shorten in parallel with
the APD in Scn5a+/− hearts owing to the selective nature of
the AP shortening in the RV epicardium, with other
ventricular regions less affected. The ECG represents a
transthoracic interpretation of the electrical vector through
the whole myocardium, and therefore, regions showing
selective electrical changes are likely to be underrepresented.
In contrast, increased transmural gradients of repolarization
times may manifest as a prolonged QTc, as electrical
repolarization would be recorded across a wider time frame.
Danik et al11 found that the QTc interval was not correlated
with the APD in murine studies.QT dispersion as an indication of
repolarization heterogeneity
Although there is disagreement to the extent that QT
dispersion represents repolarization heterogeneities,23 there
is evidence that it is useful in risk assessment in ischemia,
chronic heart failure, and long QT syndrome. There remains
controversy over the usefulness of QT dispersion as a marker
of risk in BrS, with studies either supporting or refuting its
value.24,25 Nevertheless, Na+ channel–blocking agents do
appear to increase temporal QT dispersion in patients with
BrS.20 We could not find clinical studies investigating the
effect of quinidine on ECG dispersions in BrS. Our
findings of heightened QT dispersion in Scn5a+/− hearts,
further increased by flecainide but not by quinidine,
directly parallel the respective pro- and antiarrhythmic
effects of the 2 drugs experimentally and clinically.
Furthermore, recent studies have implicated increased
repolarization gradients across the RV wall in the
arrhythmogenic mechanism in Scn5a+/− mice, which are
increased by flecainide but reduced by quinidine.6
In conclusion, this article has extended analysis of BrS from
limited pharmacological models in cellular or tissue prepara-
tions to a genetic Scn5a+/−model using the intact mouse. The
model reproduces the clinical Brugada phenotype, lending
weight to studies using it to investigate arrhythmogenic
mechanisms.We attribute conduction abnormalities inBrS to a
Na+ channel defect. Localized precordial ST elevation may
reflect specific RV repolarization abnormalities. Finally, we
show that the QT interval derived from the ECG is not a direct
correlate of APD in a specific cardiac region but suggest that
QT dispersion, as an indicator of increased transmural
repolarization gradients, may be used in clinical risk
assessment. Future studies measuring QT intervals simulta-
neously with monophasic action potentials could further
investigate this.
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